Buying Insulet (PODD)? Here's What You Must Know.

Shares of Insulet have moved -2.2% today, and are now trading at a price of $170.92. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 938,864 compared to the stock's average volume of 967,564.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Based in Acton, United States the company has 2,600 full time employees and a market cap of $11,933,822,976.

The company is now trading -40.24% away from its average analyst target price of $286.0 per share. The 16 analysts following the stock have set target prices ranging from $208.0 to $360.0, and on average give Insulet a rating of buy.

Over the last 12 months PODD shares have declined by -33.0%, which represents a difference of -49.0% when compared to the S&P 500. The stock's 52 week high is $335.91 per share and its 52 week low is $166.03. Based on Insulet's average net margin growth of 0.9% over the last 6 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023-02-24 1,305,300 4,600 0 -100.0
2022-02-24 1,098,800 16,800 2 100.0
2021-02-24 904,400 6,800 1 -50.0
2020-02-26 738,200 11,600 2 100.0
2019-02-28 563,800 3,300 1 116.67
2018-02-22 463,768 -26,831 -6
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS